Key Takeaways Novartis lifted its 2024-2029 sales outlook to 6% and projects 5-6% annual growth through 2030.Stronger guidance reflects momentum from key drugs and recent launches despite U.S. generics.Kisqali and Scemblix saw sharp third-quarter sales jumps, prompting higher peak-sales forecasts.Novartis (NVS) recently held an investor event, wherein management projected sales to grow at a compounded annual growth rate (CAGR) of 5-6% (at constant currencies) for 2025-2030.Management also upgraded its sales ...

Novartis AG (NYSE:NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade. • NVS is having a challenging session. See the full story here.The company updated its mid-term outlook ahead of its Meet Novartis Management event in London, emphasizing higher confidence in long-term demand drivers and upcoming drug launches.The drugmaker now anticipates a compound annual sal ...

市场消息 美联储决策迷雾未散！迟来的9月非农数据难以照亮降息前景。美国劳工统计局将于周四发布9月份的非农就业数据，从而结束 因政府停摆导致的官方就业数据空白期——尽管这份数据提供的无疑是过时信息。该报告预计将显示非农就业人数增加5万 人，高于最初报告的8月份的2.2万人，但仍表明劳动力市场疲软。由于这些是9月份的数据，它们对试图在艰难局面中寻找方向 的政策制定者帮助有限，并可能被市场忽视。美联储主席鲍威尔最近将这种情况比作"在雾中驾驶"，并告诫不要将进一步降息 视为板上钉钉。 AI热潮还在持续赋能!巴克莱看好大型科技股引领标普500指数突破7400点。巴克莱策略师将2026年底标普500指数的目标预期上 调至7400点，较该基准指数周三收盘位6642.16点有11.4%的潜在涨幅，理由是超大市值科技股的强势，以及尽管经济增长缓 慢，但货币和财政环境有所改善。7400点的目标较此前7000点的目标上调了5.7%。该行策略师还将标普500指数2026年的每股 收益目标从295美元上调至305美元，因为他们认为科技行业的利润增长将超过华尔街的普遍预期，"超大市值公司在宏观低增长 环境中继续表现出色，且人工智能竞赛没 ...

盘前市场动向 1. 11月20日(周四)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.56%，标普500指数期货涨1.17%，纳指期货涨 1.60%。 | = US 30 | 46,395.50 | 46,498.20 | 46,150.50 | +256.70 | +0.56% | | --- | --- | --- | --- | --- | --- | | = US 500 | 6.720.10 | 6,736.90 | 6.674.30 | +77.90 | +1.17% | | 트 US Tech 100 | 25,034.60 | 25,124.60 | 24,876.30 | +394.10 | +1.60% | 2. 截至发稿，德国DAX指数涨0.74%，英国富时100指数涨0.46%，法国CAC40指数涨0.65%，欧洲斯托克50指数涨0.81%。 | 德国DAX30 | 23,376.65 | 23,454.15 | 23,311.50 | +172.51 | +0.74% | | --- | --- | --- | --- | --- | --- | | 瑞 英国富时100 | ...

Novartis (NYSE:NVS) Update / Briefing November 20, 2025 03:00 AM ET Company ParticipantsVasant Narasimhan - CEOSloane Simpson - Head of Investor RelationsSimon Lake - Head of Equity Capital MarketsConference Call ParticipantsSachin James - AnalystMatthew Weston - Pharmaceutical Research AnalystFlorent Cespedes - Senior AnalystSteve Schaller - AnalystNone - AnalystNone - AnalystNone - AnalystSloane SimpsonAll right. Hello, everyone, and welcome to our 2025 Meet Novartis Management Investor event. Thank you, ...

该公司表示，其八款最具潜力的获批药物每款的潜在销售峰值都在30亿至100亿美元之间。 上个月，该公司以120亿美元的价格收购了Avidity Biosciences，以增加肌肉疾病治疗药物的候选产品， 这是其为抵消现有产品(包括其心力衰竭药物Entresto)销售下滑而采取的更广泛举措的一部分。该公司曾 表示，此次收购计划将使其2024至2029年的年销售额增长率预测提高到6%，高于此前预期的5%。 诺华制药(NVS.US)预计，到2030年，经汇率调整后的销售额将增长5%至6%。这得益于其抗癌药物 Kisqali和Scemblix的营收预期将达到更高水平。这家制药公司上调了Kisqali(用于治疗一种常见的乳腺 癌)的峰值销售额预测，从之前的80亿美元上调至至少100亿美元。对于白血病药物Scemblix，诺华公司 现在预计其峰值销售额至少为40亿美元，高于之前的至少30亿美元的预期。 ...

Core Insights - Novartis projects currency-adjusted sales growth of 5% to 6% until 2030 [1] - Growth is supported by higher peak revenue expectations for drugs Kisqali and Scemblix [1] Company Summary - Novartis anticipates sustained sales growth driven by its pharmaceutical portfolio [1] - The company is focusing on maximizing the revenue potential of its key drugs [1] Industry Context - The pharmaceutical industry is expected to see growth influenced by innovative drug developments [1] - Market dynamics may favor companies with strong product pipelines and revenue forecasts [1]

Core Insights - Novartis has updated its mid-term sales guidance for 2025-2030 to a compound annual growth rate (CAGR) of +5-6% at constant currencies, reflecting strong growth momentum from existing products and upcoming launches [2][7] - The company has raised peak sales guidance for key products, now identifying eight de-risked, in-market assets with peak sales potential ranging from USD 3 billion to USD 10 billion [2][8] - Novartis anticipates over 15 potentially submission-enabling readouts in the next two years, supported by a robust pipeline of more than 30 high-value medicines [3][7] Financial Performance - Novartis achieved a core operating income margin of 41.2% in the first nine months of 2025, ahead of its plan, and expects to maintain margins above 40% by 2029 despite some dilution from the acquisition of Avidity Biosciences [4][5] - The company has executed over 30 strategic deals in the past two years, enhancing its pipeline and long-term growth outlook [5] Product and Pipeline Highlights - Key products Kisqali and Scemblix have seen their peak sales forecasts increased, with Kisqali now projected to exceed USD 10 billion and Scemblix expected to reach over USD 4 billion [8] - The pipeline includes over 30 potential high-value medicines, with more than 10 licensed or acquired in the last two years, positioning Novartis for sustainable growth beyond 2030 [3][7]

Core Insights - Novartis AG reported core earnings per share of $2.25 in Q3, missing the Zacks Consensus Estimate by a penny but up from $2.06 a year ago, driven by sales growth [1][7] - Revenues reached $13.9 billion, an 8% increase year-over-year, slightly beating the Zacks Consensus Estimate [1][2] Sales Performance - On a constant currency basis, sales increased by 7%, supported by strong performances from Kisqali, Kesimpta, Scemblix, and Pluvicto, which offset the negative impact of generic competition for Promacta, Tasigna, and Entresto [2][4] - Core operating income rose 7% to $5.5 billion [2] Key Drug Performance - Kisqali sales surged 68% to $1.33 billion, driven by growth in the United States [8] - Kesimpta sales increased 44% to $1.2 billion, exceeding estimates [9] - Pluvicto sales grew 45% to $564 million, benefiting from expanded indications [11] - Entresto sales decreased 1% to $1.9 billion due to generic competition, missing estimates [5][6] - Cosentyx sales were down 1% to $1.7 billion, impacted by a one-time revenue adjustment [6] Strategic Developments - Novartis announced the acquisition of Avidity Biosciences for $12 billion to enhance its neuroscience pipeline, focusing on genetic neuromuscular diseases [18][19] - The company expects net sales to grow in high single digits and core operating income to grow in the low teens by 2025 [17] Other Updates - Novartis received FDA approval for remibrutinib as a treatment for chronic spontaneous urticaria [21] - The company is advancing its pipeline with new drug approvals and collaborations, including a licensing agreement with Arrowhead Pharmaceuticals for a preclinical-stage therapy targeting Parkinson's disease [27]

Financial Performance - Novartis reported a 7% increase in net sales and core operating income for Q3 2025, with a core margin of 39.3% [5][27] - Core EPS rose by 10% to $2.25, and free cash flow totaled $6.2 billion for the quarter [28][27] - For the first nine months, net sales grew by 11%, core operating income by 18%, and core EPS increased by 21% to $6.94 [28][29] Business Line Performance - Key brands showed strong growth: Kisqali grew 68%, Pluvicto 45%, Leqvio 54%, and Scemblix 95% in constant currency [6][10][14][16] - Kisqali's U.S. growth was particularly strong at 91%, with a market-leading position in both metastatic and early breast cancer [7][9] - Pluvicto's growth was driven by new patient starts, with U.S. sales up 53% [11][12] - Leqvio is on track for over $1 billion in sales, with significant growth in both the U.S. and international markets [14][15] - Scemblix is expected to become the most prescribed TKI in the U.S. [16] Market Performance - The U.S. experienced negative growth due to net true-ups related to Medicare Part D redesign, but underlying growth would have been 9% without these adjustments [27][28] - Outside the U.S., Kisqali saw 37% growth in constant currency, and Pluvicto is expanding in Europe, Canada, and Brazil [7][12] - The renal portfolio, particularly IGAN, grew 98% in the U.S., significantly outpacing market growth [20][21] Company Strategy and Industry Competition - Novartis is focused on driving growth through its priority brands and pipeline advancements, despite facing generic erosion from products like Entresto [5][28] - The company is pursuing strategic acquisitions, including Avidity Biosciences, to enhance its growth trajectory [35][36] - Novartis aims to maintain a core margin of around 40% despite expected short-term dilution from new product launches [35][36] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in mid to long-term growth, reaffirming guidance for high single-digit growth in net sales and low teens growth in core operating income for the full year [31][38] - The company anticipates challenges in the first half of 2026 due to generic competition but expects a stronger second half [33][34] - Management highlighted the importance of addressing pricing and reimbursement issues with the administration to support innovation [41][42] Other Important Information - Novartis is preparing for regulatory submissions for several products, including remibrutinib and ianalumab, with expectations for rapid uptake in the market [22][24] - The company is focused on enhancing its R&D capabilities and expanding its manufacturing base in the U.S. [43] Q&A Session Summary Question: Impact of Medicaid and tariffs on the industry - Management indicated that while some companies have reached agreements with the administration, Novartis is in ongoing discussions to find suitable solutions [41][42] Question: CapEx and cash flow modeling - Management clarified that the majority of the $23 billion commitment over five years is for R&D OpEx, with CapEx expected to remain stable at 2.5%-3% of sales [42][43] Question: Market reaction to ATR abstract - Management expressed confidence that detailed data presentation would improve market perception and emphasized the importance of patient benefits over statistical measures [46][47] Question: Pluvicto launch curve and peak sales ambition - Management stated that Pluvicto is on a strong growth trajectory, expecting to reach peak sales of $5 billion with ongoing efforts to tackle commercialization challenges [55][56][58] Question: Remibrutinib ramp-up and European adoption - Management highlighted the focus on payer negotiations and the potential for rapid uptake in the U.S. and Europe, emphasizing the innovative profile of remibrutinib [62][64] Question: Ianalumab study results and secondary endpoints - Management explained the statistical significance achieved in primary endpoints and the importance of patient-relevant outcomes for future discussions with physicians [68][71] Question: Cosentyx market share and new formulation - Management noted that there has been no significant impact from competitor launches and emphasized ongoing efforts to maintain market share in a growing market [74]